Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism

Abraham RT, Wiederrecht GJ . (1996). Immunopharmacology of rapamycin. Annu Rev Immunol 14: 483–510.

Dagher R, Helman L . (1999). Rhabdomyosarcoma: an overview. Oncologist 4: 34–44.

Fingar DC, Blenis J . (2004). Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151–3171.

Fingar DC, Salama S, Tsou C, Harlow E, Blenis J . (2002). Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16: 1472–1487.

Goetsch L, Gonzalez A, Leger O, Beck A, Pauwels PJ, Haeuw JF et al. (2005). A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 113: 316–328.

Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS et al. (2002). Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 277: 30958–30967.

Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, Rebholz H et al. (2004). The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166: 213–223.

Hay N . (2005). The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8: 179–183.

Hay N, Sonenberg N . (2004). Upstream and downstream of mTOR. Genes Dev 18: 1926–1945.

Hidalgo M, Rowinsky EK . (2000). The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19: 6680–6686.

Huang S, Houghton PJ . (2003). Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3: 371–377.

Inoki K, Li Y, Zhu T, Wu J, Guan KL . (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648–657.

Kido Y, Burks DJ, Withers D, Bruning JC, Kahn CR, White MF et al. (2000). Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest 105: 199–205.

Lawlor MA, Alessi DR . (2001). PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 114: 2903–2910.

LeRoith D, Baserga R, Helman L, Roberts Jr CT . (1995). The role of the insulin-like growth factor-I receptor in cancer. Ann NY Acad Sci 766: 402–408.

LeRoith D, Helman L . (2004). The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell 5: 201–202.

Manning BD . (2004). Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 167: 399–403.

Merlino G, Helman L . (1999). Rhabdomyosarcoma – working out the pathways. Oncogene 18: 5340–5348.

Minniti CP, Luan D, O’Grady C, Rosenfeld RG, Oh Y, Helman LJ . (1995). Insulin-like growth factor II overexpression in myoblasts induces phenotypic changes typical of the malignant phenotype. Cell Growth Differ 6: 263–269.

O’Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500–1508.

Pappo AS, Shapiro DN, Crist WM, Maurer HM . (1995). Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 13: 2123–2139.

Potter CJ, Pedraza LG, Xu T . (2002). Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol 4: 658–665.

Radimerski T, Montagne J, Hemmings-Mieszczak M, Thomas G . (2002). Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6 K signaling. Genes Dev 16: 2627–2632.

Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H et al. (2004). Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14: 1296–1302.

Sarbassov DD, Guertin DA, Ali SM, Sabatini DM . (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098–1101.

Schmelzle T, Hall MN . (2000). TOR, a central controller of cell growth. Cell 103: 253–262.

Shah OJ, Wang Z, Hunter T . (2004). Inappropriate activation of the TSC/Rheb/mTOR/S6 K cassette induces IRS1/2 depletion, insulin resistance and cell survival deficiencies. Curr Biol 14: 1650–1656.

Stocker H, Radimerski T, Schindelholz B, Wittwer F, Belawat P, Daram P et al. (2004). Rheb is an essential regulator of S6 K in controlling cell growth in Drosophila. Nat Cell Biol 5: 559–565.

Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H et al. (2005). Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65: 7052–7058.

Sun XJ, Rothenberg P, Kahn CR, Backer JM, Araki E, Wilden PA et al. (1991). Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352: 73–77.

Tremblay F, Marette A . (2001). Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 276: 38052–38060.

Wan X, Helman LJ . (2002). Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway. Neoplasia 4: 400–408.

Wan X, Helman LJ . (2003). Levels of PTEN protein modulate Akt phosphorylation on serine 473, but not on threonine 308, in IGF-II-overexpressing rhabdomyosarcomas cells. Oncogene 22: 8205–8211.

Wan X, Mendoza A, Khanna C, Helman LJ . (2005). Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. Cancer Res 65: 2406–2411.

White MF . (1998). The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol Cell Biochem 182: 3–11.

Womer RB, Pressey JG . (2000). Rhabdomyosarcoma and soft tissue sarcoma in childhood. Curr Opin Oncol 12: 337–344.

Zhang L, Kim M, Choi YH, Goemans B, Yeung C, Hu Z et al. (1999). Diminished G1 checkpoint after gamma-irradiation and altered cell cycle regulation by insulin-like growth factor II overexpression. J Biol Chem 274: 13118–13126.